Literature DB >> 21364683

Personalized cancer medicine: era of promise and progress.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21364683     DOI： 10.1038/nrclinonc.2011.14

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry.

Authors:  Erin Shammel Baker; Kristin E Burnum-Johnson; Jon M Jacobs; Deborah L Diamond; Roslyn N Brown; Yehia M Ibrahim; Daniel J Orton; Paul D Piehowski; David E Purdy; Ronald J Moore; William F Danielson; Matthew E Monroe; Kevin L Crowell; Gordon W Slysz; Marina A Gritsenko; John D Sandoval; Brian L Lamarche; Melissa M Matzke; Bobbie-Jo M Webb-Robertson; Brenna C Simons; Brian J McMahon; Renuka Bhattacharya; James D Perkins; Robert L Carithers; Susan Strom; Steven G Self; Michael G Katze; Gordon A Anderson; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2014-01-08       Impact factor: 5.911

2.  P5 medicine: a plus for a personalized approach to oncology.

Authors:  Alessandra Gorini; Gabriella Pravettoni
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

Review 3.  Clinical phenotype network: the underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine.

Authors:  Xuezhong Zhou; Yubing Li; Yonghong Peng; Jingqing Hu; Runshun Zhang; Liyun He; Yinghui Wang; Lijie Jiang; Shiyan Yan; Peng Li; Qi Xie; Baoyan Liu
Journal:  Front Med       Date:  2014-08-12       Impact factor: 4.592

4.  From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and "augmented" medicine: some considerations on Salvatore Iaconesi's clinical story.

Authors:  Nicola Luigi Bragazzi
Journal:  Patient Prefer Adherence       Date:  2013-04-24       Impact factor: 2.711

Review 5.  Somatic variation and cancer: therapies lost in the mix.

Authors:  Andrew V Biankin; Thomas J Hudson
Journal:  Hum Genet       Date:  2011-06-05       Impact factor: 5.881

6.  Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases.

Authors:  Ludovica Grassi; Romina Alfonsi; Federica Francescangeli; Michele Signore; Maria Laura De Angelis; Antonio Addario; Manuela Costantini; Elisabetta Flex; Andrea Ciolfi; Simone Pizzi; Alessandro Bruselles; Matteo Pallocca; Giuseppe Simone; Mustapha Haoui; Mario Falchi; Michele Milella; Steno Sentinelli; Paola Di Matteo; Emilia Stellacci; Michele Gallucci; Giovanni Muto; Marco Tartaglia; Ruggero De Maria; Désirée Bonci
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

7.  Outlier kinase expression by RNA sequencing as targets for precision therapy.

Authors:  Vishal Kothari; Iris Wei; Sunita Shankar; Shanker Kalyana-Sundaram; Lidong Wang; Linda W Ma; Pankaj Vats; Catherine S Grasso; Dan R Robinson; Yi-Mi Wu; Xuhong Cao; Diane M Simeone; Arul M Chinnaiyan; Chandan Kumar-Sinha
Journal:  Cancer Discov       Date:  2013-02-05       Impact factor: 39.397

Review 8.  Mass spectrometry for translational proteomics: progress and clinical implications.

Authors:  Erin Shammel Baker; Tao Liu; Vladislav A Petyuk; Kristin E Burnum-Johnson; Yehia M Ibrahim; Gordon A Anderson; Richard D Smith
Journal:  Genome Med       Date:  2012-08-31       Impact factor: 11.117
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.